PALO ALTO, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Open Monoclonal Technology, Inc. (OMT) and Crystal Bioscience, Inc. (Crystal) today announced a strategic alliance where OMT will access Crystal’s deep antibody screening technology, Gel-Encapsulated Microenvironment (GEM. With this transaction, OMT formally launches “OmniAb™”, a new integrated antibody discovery suite with superior protein and DNA immunization, OMT’s proprietary OmniRat™ transgenic animals, and the GEM deep antibody screening technology. The GEM technology facilitates “minimal loss” identification of all antibodies with specific target and other therapeutically relevant characteristics across large lymphocyte populations and greatly reduces the time and cost associated with identification of candidate therapeutic antibodies. The assay involves bringing single antibody-secreting lymphocytes in proximity with cell or bead reporters within each GEM. The antibodies can diffuse locally within the GEM, bind to the reporters, and be detected visually or with secondary antibodies. Each GEM may contain multiple reporters for single-step differentiation of therapeutic features.
